Amicus Therapeutics
Open
$14.50
Prev. Close
$14.50
High
$14.50
Low
$14.50
Market Snapshot
$4.47B
-164.9
-0.18
$528.3M
511
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 511 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
BioMarin's acquisition of Amicus Therapeutics has resulted in its delisting from Nasdaq, concluding Amicus’s independent operations in the biotechnology sector.
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 511 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Recently from Cashu
FDA Approves Palynziq for PKU: A Milestone in Rare Disease Treatment Innovation
FDA Approval Expands Treatment Options for PKU Patients: A Catalyst for Innovation in Rare Disease Management In a significant development for the biopharmaceutical sector focused on rare diseases, th…
BioMarin's Palynziq Approval: A Milestone in Treating Rare Disease PKU for Adolescents
Innovative Approaches in Rare Disease Treatments: BioMarin's New Opportunity for PKU Patients The recent FDA approval of BioMarin Pharmaceutical Inc.'s Palynziq (pegvaliase-pqpz) for adolescents 12 ye…
Amicus Therapeutics Faces Legal Challenges Amid Drug Price Control Controversy
Legal Challenges to Drug Price Controls: A Crucial Moment for Pharmaceutical Innovation Amicus Therapeutics, a biopharmaceutical company focused on developing advanced therapies for rare and orphan di…
Amicus Therapeutics Under Legal Investigation Amid BioMarin Acquisition Talks
Amicus Therapeutics Faces Legal Scrutiny Amid Acquisition Talks Amicus Therapeutics, a biopharmaceutical company specializing in treatments for rare genetic diseases, finds itself at the center of an…